source
- Biotech Index Surges as IPOs and M&A Activity Accelerate in 2026The XBI biotech index, which had fallen to about $64 per share three years ago, has climbed back to near $170, almost doubling its value over the past year. Investor interest is reflected in a wav…
- AstraZeneca and Ionis report unexpected failure of heart disease drug in trialAstraZeneca and Ionis disclosed that their collaborative heart disease drug did not meet primary endpoints in a recent trial, marking a surprise setback. The companies detailed the trial results,…